Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

220,291-220,320 of 319,975

filter-aware
03
Uses a hub-and-spoke diagram to represent the company's strategic pillars.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a Gantt-style visualization for drug development stages.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Golden Circle1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
06
Includes specific financial breakdown of deal value and R&D funding obligations.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a side-by-side comparison structure to detail trial status and upcoming milestones for two distinct clinical programs.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
08
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
10
Uses a visual comparison framework to illustrate the 'Goldilocks' problem in drug development.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
12
The slide uses a hub-and-spoke visual metaphor to explain the shared signaling mechanism of the γC receptor family.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
13
The slide uses a process diagram to show the transition from native cytokine sequences to a proprietary composite sequence, resulting in an engineered inhibitor.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
14
The slide uses a biological mechanism diagram to illustrate how the inhibitor selectively targets specific cytokines (A, D, F) while leaving others unaffected.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
15
The slide uses a visual mechanism to show how different inhibitors interact with cell signaling pathways.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
16
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
18
The slide uses a column-based layout to compare four distinct disease indications.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes before/after clinical photos and a comparative table against Mogamulizumab.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
21
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing efficacy against PBS and Ruxolitinib.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using two different chart types (line chart with negative values vs line chart with positive values) to demonstrate efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a specific callout for a Blackbox warning on existing competitors.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
Includes a timeline-style process diagram for the study phases.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
27
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
28
The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a biological process diagram and a gene expression heatmap.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strategy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit